Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Presentation / Abstract • Phase 1ESGCT late-breaking poster presentation Tue, Oct 27, 2026
Company profile
Benitec Biopharma Inc.
Pipeline1 asset
- BB-301BB-301 / PABPN1 / AAV ddRNAi silence-and-replace genetic medicine / Rare disease; neuromuscularOculopharyngeal muscular dystrophy (OPMD)Phase 1b/2aClinical-stage
Latest news4 items
All newsBenitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Presentation / Abstract • Phase 1/2ESGCT presentation Tue, Oct 27, 2026
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Presentation / Abstract • Phase 1ASGCT oral presentation Fri, May 15, 2026, 8:00 AM EDT